# A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct06256549` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06256549](<https://clinicaltrials.gov/study/NCT06256549>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06256549

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 272 participants.

## Technical summary

Registry record NCT06256549. Randomized; no masking; primary purpose treatment. Start 2023-08-09 (actual); primary completion 2024-07-20 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 272 participants (enrolled count; ClinicalTrials.gov record NCT06256549, source copy `cardio:ctgov-nct06256549-2024-02-23`, retrieved 2026-10-26)
- Started: 2023-08-09 (actual) (ClinicalTrials.gov record NCT06256549, source copy `cardio:ctgov-nct06256549-2024-02-23`, retrieved 2026-10-26)
- Primary completion: 2024-07-20 (anticipated) (ClinicalTrials.gov record NCT06256549, source copy `cardio:ctgov-nct06256549-2024-02-23`, retrieved 2026-10-26)
- Completion: 2024-07-20 (anticipated) (ClinicalTrials.gov record NCT06256549, source copy `cardio:ctgov-nct06256549-2024-02-23`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06256549, source copy `cardio:ctgov-nct06256549-2024-02-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06256549-2024-02-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes
- Intervention (Drug): GZR18
- Intervention (Drug): Semaglutide
- Lead sponsor: Gan and Lee Pharmaceuticals, USA
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Gan and Lee Pharmaceuticals, USA (`cardio:org-gan-and-lee-pharmaceuticals-usa`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial (`cardio:pubmed-42372276`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 4ccfa9b40f05b2d3875b37a5599541e50e5a5180f1a584fafc0388a64aafffc3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
